The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. VistaGen Therapeutics Inc. shares valued at $17,870 were purchased by GIN JERRY B on Aug 18. At $0.18 per share, GIN JERRY B acquired 100,000 shares. The insider’s holdings grew to 100,000 shares worth approximately $16000.0 following the completion of this transaction.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
Also, GIN JERRY B purchased 100,000 shares, netting a total of over 17,870 in proceeds. Following the buying of shares at $0.18 each, the insider now holds 100,000 shares.
Before that, Singh Shawn had added 600,000 shares to its account. In a trade valued at $103,200, the CHIEF EXECUTIVE OFFICER bought VistaGen Therapeutics Inc. shares for $0.17 each. Upon closing the transaction, the insider’s holdings increased to 600,000 shares, worth approximately $0.1 million.
As published in a research note from William Blair on July 22, 2022, VistaGen Therapeutics Inc. [VTGN] has been rated down from an Outperform to a Mkt perform. Analysts at Robert W. Baird downgraded the stock from ‘”an Outperform”‘ to ‘”a Neutral”‘ outlook in a report released in late July. As of July 22, 2022, Jefferies has decreased its “Buy” rating to a “Hold” for VTGN. Earlier on May 20, 2021, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for VTGN stock.
Analyzing VTGN’s Price Performance
On Wednesday, VistaGen Therapeutics Inc. [NASDAQ: VTGN] plunged -5.22% to $0.16. The stock’s lowest price that day was $0.1611, but it reached a high of $0.1745 in the same session. During the last five days, there has been a drop of approximately -13.83%. Over the course of the year, VistaGen Therapeutics Inc. shares have dropped approximately -91.63%. Shares of the company reached a 52-week high of $2.1100 on 01/04/22 and a 52-week low of $0.1388 on 08/01/22. A 50-day SMA is recorded $0.2742, while a 200-day SMA reached $1.0945. Nevertheless, trading volume fell to 5.11 million shares from 3.52 million shares the previous day.
Support And Resistance Levels for VistaGen Therapeutics Inc. (VTGN)
According to the 24-hour chart, there is a support level at 0.1581, which, if violated, would cause prices to drop to 0.1529. In the upper region, resistance lies at 0.1715. The next price resistance is at 0.1797. RSI (Relative Strength Index) is 35.84 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0108, which suggests the price will decrease in the coming days. Percent R is at 96.12%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is VistaGen Therapeutics Inc. subject to short interest?
Stocks of VistaGen Therapeutics Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 2.62 million shares to 16.77 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 14.15 million shares. A jump of 15.62% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.17 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.17.
Which companies own the most shares of VistaGen Therapeutics Inc. (VTGN)?
According to Commodore Capital LP filings, the company currently owns 13,049,079 shares, which is about 6.31% of the total VTGN shares outstanding. The investor’s shares have appreciated by 2,951,850 from its previous 13-F filing of 10097229.0 shares. With the completion of the sale transaction, Acuta Capital Partners LLC’s stake is now worth $2,090,507. BlackRock Fund Advisors reduced a -0.01% interest valued at $1.98 million while The Vanguard Group, Inc. purchased a 727,072 stake. A total of -491,583 shares of VistaGen Therapeutics Inc. were bought by Franklin Advisers, Inc. during the quarter, and -114,551 were sold by Nicholas Investment Partners LP. In its current portfolio, SSgA Funds Management, Inc. holds 3,895,398 shares valued at $0.72 million.
In spite of this, 4 analysts ranked VistaGen Therapeutics Inc. stock as a Hold at the end of 2022. On February 18, 2021, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $6.